Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (19)

2024

  1. Patient-reported outcome measures in severe asthma: an expert consensus

    Journal of Asthma, Vol. 61, Núm. 6, pp. 619-631

2023

  1. Agreement between pharmacists and physicians on the assessment of appropriateness of antimicrobial prescribing

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Telemedicine and severe asthma in our environment: Views on the experience of professionals and suggestions to make it a reality

    Open Respiratory Archives, Vol. 5, Núm. 3

  4. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

    Frontiers in Public Health, Vol. 11

2022

  1. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953

  2. Cuadro de mando de Telefarmacia: Indicadores de actividad y calidad de la atención farmacéutica de un servicio de farmacia de hospital

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 7, pp. 92-105

  3. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

    The Journal of infectious diseases, Vol. 225, Núm. 6, pp. 1040-1049

  4. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

    Acta Dermato-Venereologica, Vol. 102

2021

  1. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  2. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2018

  1. Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis

    BioDrugs, Vol. 32, Núm. 3, pp. 281-291

2017

  1. Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: An agreement among hospital pharmacists for the standardized collection of a minimum set of data

    Farmacia Hospitalaria, Vol. 41, Núm. 1, pp. 31-48

2014

  1. Algoritmo de diagnóstico y tratamiento del angioedema hereditario como herramienta para su manejo (Farmacia Hospitalaria (2013) 37, 6 (521-529))

    Farmacia Hospitalaria

2012

  1. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2009

  1. Micronutrientes en nutrición parenteral

    Nutricion Hospitalaria, Vol. 24, Núm. 2, pp. 152-155

2004

  1. Surgery in haemophilic patients with inhibitor: 20 years of experience

    Haemophilia, Supplement, Vol. 10, Núm. 2, pp. 30-40